

# Anne Sophie Koldkjær Salling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1078114/publications.pdf>

Version: 2024-02-01

9  
papers

245  
citations

1307594

7  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

318  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study. <i>Osteoporosis International</i> , 2021, 32, 1103-1115.	3.1	10
2	The predictive value of bone turnover markers during discontinuation of alendronate: the PROSA study. <i>Osteoporosis International</i> , 2021, 32, 1557-1566.	3.1	5
3	Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1858-1870.	2.8	63
4	Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1245-1254.	2.8	47
5	Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2019, 30, 995-1002.	3.1	3
6	Current Status of Bone-Forming Therapies for the Management of Osteoporosis. <i>Drugs and Aging</i> , 2019, 36, 625-638.	2.7	17
7	Non-parathyroid hypercalcemia associated with paraffin oil injection in 12 younger male bodybuilders: a case series. <i>European Journal of Endocrinology</i> , 2018, 178, K29-K37.	3.7	17
8	The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 105-115.	2.7	49
9	Hypercalcemia after discontinuation of long-term denosumab treatment. <i>Osteoporosis International</i> , 2016, 27, 2383-2386.	3.1	34